Open AccessPlasma protein profiling in a stage defined pancreatic cancer cohort – Implications for early diagnosis
Author(s) -
Gerdtsson Anna Sandström,
Wingren Christer,
Persson Helena,
Delfani Payam,
Nordström Malin,
Ren He,
Wen Xin,
Ringdahl Ulrika,
Borrebaeck Carl A.K.,
Hao Jihui
Publication year - 2016
Publication title -
molecular oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.332
H-Index - 88
eISSN - 1878-0261
pISSN - 1574-7891
DOI - 10.1016/j.molonc.2016.07.001
Subject(s) - stage (stratigraphy) , medicine , pancreatic cancer , pancreatic ductal adenocarcinoma , cohort , oncology , disease , cancer , pathology , gastroenterology , biology , paleontology
Pancreatic ductal adenocarcinoma (PDAC) is a disease where detection preceding clinical symptoms significantly increases the life expectancy of patients. In this study, a recombinant antibody microarray platform was used to analyze 213 Chinese plasma samples from PDAC patients and normal control (NC) individuals. The cohort was stratified according to disease stage, i.e. resectable disease (stage I/II), locally advanced (stage III) and metastatic disease (stage IV). Support vector machine analysis showed that all PDAC stages could be discriminated from controls and that the accuracy increased with disease progression, from stage I to IV. Patients with stage I/II PDAC could be discriminated from NC with high accuracy based on a plasma protein signature, indicating a possibility for early diagnosis and increased detection rate of surgically resectable tumors.